These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9279483)

  • 1. Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
    Noda K; Umeda F; Nawata H
    Diabetes Res Clin Pract; 1997 Aug; 37(2):129-36. PubMed ID: 9279483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL
    Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
    Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
    Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose.
    Scott RS; Knowles RL; Beaven DW
    Aust N Z J Med; 1984 Oct; 14(5):649-54. PubMed ID: 6397178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J; Spengler M
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB
    Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acarbose: in search for its real indications in current medical practice.
    Lerman I; Gómez Perez FJ; Aguilar-Salinas CA; Rodrigo JA
    Diabetes Care; 1996 Jan; 19(1):94-5. PubMed ID: 8720547
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
    Josse RG
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of acarbose treatment of NIDDM].
    Wainstein J; Jedwab M
    Harefuah; 1997 Feb; 132(4):258-63, 311. PubMed ID: 9153894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
    Santeusanio F; Compagnucci P
    Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin.
    Johansen K
    Diabete Metab; 1984 Oct; 10(4):219-23. PubMed ID: 6391973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.